Contrast-enhanced cardiac magnetic resonance in a patient with chemotoxic cardiomyopathy

Journal of Cardiovascular Medicine

Volumn 8, Issue 3, 2007, Pages 214-215

  Catalano, Oronzo ^a   Antonaci, Serena ^a   Moro, Guido ^a   Baldi, Maurizia ^a   Cobelli, Franco ^a   Opasich, Cristina ^a  

^a IRCCS   (Italy)

Author keywords

Cardiomyopathy; Cardiotoxicity; Magnetic resonance

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; GADOLINIUM; VINCRISTINE;

ACUTE HEART INFARCTION; ADULT; ANAMNESIS; ARTICLE; CARDIOMYOPATHY; CARDIOTOXICITY; CASE REPORT; CONGESTIVE CARDIOMYOPATHY; CONTRAST ENHANCEMENT; CORONARY ARTERY DISEASE; ECHOCARDIOGRAPHY; HEART FAILURE; HEART MUSCLE CELL; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAAORTIC LYMPH NODE; RHABDOMYOSARCOMA; TESTIS;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARDIOMYOPATHIES; CONTRAST MEDIA; CYCLOPHOSPHAMIDE; DOXORUBICIN; HUMANS; MAGNETIC RESONANCE IMAGING, CINE; MALE; STROKE VOLUME; VINCRISTINE;

EID: 33847160342     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/JCM.0b013e3280104155     Document Type: Article

References (14)

1. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973; 32:302-314.
2. Sudharsan PT, Mythili Y, Selvakumar E, Varalakshmi P. Lupeol and its ester ameliorate the cyclophosphamide provoked cardiac lysosomal damage studied in rat. Mol Cell Biochem 2006; 282:23-29.
3. Calvo-Romero JM, Fernandez-Soria-Pantoja R, Arrebola-Garcia JD, Gil-Cubero M. Ischemic heart disease associated with vincristine and doxorubicin chemotherapy. Ann Pharmacother 2001; 35:1403-1405.
4. Speyer JL, Green MD, Zeleniuch-Jacquotte A, Wernz JC, Rey M, Sanger J, et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 1992; 10:117-127.
5. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004; 56:185-229.
6. Gandolfi A. Adriamycin induced chronic cardiotoxicity: a morphological ultrastructural study on ventricular myocardium and conducting system of rabbit heart. Ateneo Parmense Acta Biomed 1976; 47:69-78.
7. Jaenke RS. Delayed and progressive myocardial lesions after adriamycin administration in the rabbit. Cancer Res 1976; 36:2958-2966.
8. Mauldin GE, Fox PR, Patnaik AK, Bond BR, Mooney SC, Matus RE. Doxorubicin-induced cardiotoxicosis. Clinical features in 32 dogs. J Vet Intern Med 1992; 6:82-88.
9. Kajihara H, Yokozaki H, Yamahara M, Kadomoto Y, Tahara E. Anthracycline induced myocardial damage. An analysis of 16 autopsy cases. Pathol Res Pract 1986; 181:434-441.
10. Bouhour JB, Petitier H, Delajartre AY, Fumoleau P, Rozo L, Nicolas G. Endomyocardial biopsy as a method of surveilling adriamycin cardiac toxicity: 28 biopsies in 26 patients. Arch Mal Coeur Vaiss 1983; 76:1277-1283.
11. Mortensen SA, Olsen HS, Baandrup U. Chronic anthracycline cardiotoxicity: haemodynamic and histopathological manifestations suggesting a restrictive endomyocardial disease. Br Heart J 1986; 55:274-282.
12. Lipshultz SE, Lipsitz SR, Sallan SE, Simbre VC 2nd, Shaikh SL, Mone SM, et al. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol 2002; 20:4517-4522.
13. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991; 266:1672-1677.
14. McCrohon JA, Moon JC, Prasad SK, McKenna WJ, Lorenz CH, Coats AJ, et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation 2003; 108:54-59.